Tagatose - Spherix

Drug Profile

Tagatose - Spherix

Alternative Names: D-tagatose; Naturlose

Latest Information Update: 18 May 2012

Price : $50

At a glance

  • Originator Spherix
  • Class Hexoses; Obesity therapies; Small molecules
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Suspended Type 2 diabetes mellitus
  • Discontinued Hypertriglyceridaemia

Most Recent Events

  • 29 Mar 2012 Discontinued - Preclinical for Hypertriglyceridaemia in USA (unspecified route)
  • 21 Jan 2011 Spherix completes a phase II trial in Type-2 diabetes mellitus in USA and India (NCT00961662)
  • 09 Dec 2010 Efficacy data from a phase II trial in Type-2 diabetes mellitus released by Spherix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top